FindMyKOL
Clinical trialNCT00719914TerminatedPhase 2Interventional

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

NCT00719914 is a phase 2 interventional trial sponsored by Brigham and Women's Hospital. As of 21 Nov 2026, it was terminated. It studies Eptifibatide and Normal saline in ST-Elevation Myocardial Infarction. The registry lists an enrollment of 31 participants at 3 sites in 1 country. The registry lists a start date of 30 Nov 2007 and a primary completion date of 30 Nov 2008.

SponsorBrigham and Women's Hospital →Enrollment31ST-Elevation Myocardial Infarction
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00719914
FieldValue
Registry IDNCT00719914
StatusTerminated
PhasePhase 2
Study typeInterventional trial
Lead sponsorBrigham and Women's Hospital
Enrollment31
Registered sites3
Countries1
ConditionsST-Elevation Myocardial Infarction
DrugsEptifibatide and Normal saline
Start30 Nov 2007
Primary completion30 Nov 2008
Study completion31 Jan 2009
Last update posted27 Aug 2012

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly after arriving. This drug is usually given through a vein in the arm. However, eptifibatide can also be injected directly into the heart's blood supply just before angioplasty, a common procedure to unblock a blood vessel in the heart. This new way of giving the drug is being studying.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • Cardiology Research Associates

    Ormond Beach

Michigan, United States1 site
  • Crittenton Hospital Medical Center

    Rochester

Ohio, United States1 site
  • Mid Ohio Heart Clinic

    Mansfield

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 siteMI1New YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 siteOH1PennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EptifibatideNormal saline
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00719914

Each answer restates registry values shown on this page.

What is NCT00719914?

NCT00719914 is a phase 2 interventional trial sponsored by Brigham and Women's Hospital. It studies Eptifibatide and Normal saline in ST-Elevation Myocardial Infarction.

Who leads NCT00719914?

The registry names C. Michael Gibson, M.D. (principal investigator, The TIMI Study Group) and Eugene Braunwald, M.D. (study chair, The TIMI Study Group) as overall officials.

Where does NCT00719914 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00719914 study?

The registered drug and biological interventions are Eptifibatide and Normal saline.

When did NCT00719914 end?

The registry lists a primary completion date of 30 Nov 2008 and a study completion date of 31 Jan 2009. The sponsor last updated the record on 27 Aug 2012.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.